Testing a radiation drug for meningioma that has come back
Official title: Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests a drug that carries radiation to meningioma tumors that grew back after earlier treatment.
Read our full plain-language summary
What the trial team says
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Key facts
- Registry number
- NCT06955169
- Stage of testing
- Phase 2
- Conditions studied
- Intracranial Meningioma
Where it is running
This trial lists 17 sites.
-
California
- University of California, Irvine (Irvine)
- University of California San Diego - Moores Cancer Center (La Jolla)
-
Connecticut
- Yale University (New Haven)
-
Florida
- Baptist MD Anderson Cancer Center (Jacksonville)
- University of Miami (Miami)
- Baptist Health Medical Group Oncology (Miami)
- Moffitt Cancer Center (Tampa)
-
Georgia
- Piedmont Healthcare (Atlanta)
-
Indiana
- Indiana University (Indianapolis)
-
Iowa
- University of Iowa Health Care (Iowa City)
-
Massachusetts
- Dana-Farber/Harvard Cancer Center (Boston)
-
Michigan
- University of Michigan Rogel Cancer Center (Ann Arbor)
- Henry Ford Hospital (Detroit)
-
New York
- NYU Lagone Health (New York)
-
North Carolina
- Duke University Medical Center (Durham)
-
Texas
- MD Anderson Cancer Center (Houston)
-
Wisconsin
- Medical College of Wisconsin (Milwaukee)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.